AbbVie files Rinvoq for psoriatic arthritis
Rinvoq is a selective and reversible JAK inhibitor being studied in several immune-mediated inflammatory diseases
Read More
Tag: ACR20
Positive late stage rheumatoid arthritis trial results for Abbvie
Upadacitinib was found to have achieved both primary endpoints with significantly higher rates of ACR20 response and low disease activity at week 14.
Read More
First PhIII trial of AbbVie’s upadacitinib a success
AbbVie’s experimental drug upadacitinib has hit primary and secondary targets in the first late-stage trial of the drug involving patients with moderate-to-severe rheumatoid arthritis (RA).
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
